Table 4. Univariate and multivariate analyses of risk factors for predicting HCC with coexistence of HBsAg/anti-HBs development.
| Factors | HCC (n = 76) | Non-HCC (n = 212) | Univariate | Multivariate | |
|---|---|---|---|---|---|
| P value | Odds ratio | P value | |||
| Male [n (%)] | 60 (78.94%) | 173 (81.60%) | 0.549 | 0.548 (0.236-1.277) | 0.164 |
| Age >40 | 69 (90.79%) | 132 (70.97%) | < 0.001 | 3.005 (1.177-7.674) | 0.021 |
| AFP >10 ng/mL | 59 (77.63%) | 86 (40.57%) | < 0.001 | 4.718 (2.406-9. 251) | < 0.001 |
| Liver cirrhosis | 68 (89.45%) | 115 (54.24%) | < 0.001 | 6.844 (2.773-16.891) | < 0.001 |
| HBV genotype C [n (%)] | 75 (98.68%) | 198 (93.40%) | 0.075 | 7.960 (0.847-74.841) | 0.070 |
| HBV DNA (log10 IU/mL) | |||||
| 1 (2.23-3.99) | 26 (34.21%) | 45 (21.22%) | 0.068 | 1.320 (0.392-4.440) | 0.654 |
| 2 (4-5.99) | 22 (28.94%) | 69 (32.55%) | 0.607 | 1.008 (0.304-3.334) | 0.990 |
| 3 ( ≥6) | 20 (26.31%) | 75 (35.38%) | 0.168 | 0.773 (0.220-2.438) | 0.612 |
| HBeAg negative [n (%)] | 33 (43.42%) | 50 (23.85%) | < 0.001 | 2.218 (1.134-4.335) | 0.020 |
| N-glycosylation mutation [n (%)] | 17 (22.37%) | 17 (8.02%) | < 0.001 | 2.831 (1.157-6.929) | 0.023 |
95% CI, confidence interval; ALT, alanine aminotransferase; AFP, alpha-fetoprotein; HCC, hepatocellular carcinoma.